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RuSH—Strategies from the Field: Data Collection
Overview
In 2010, the Registry and Surveillance System for 
Hemoglobinopathies (RuSH) pilot project was implemented by 
the Centers for Disease Control and Prevention (CDC) to collect 
state-specific, population-based data on people with sickle 
cell disease (SCD) and thalassemia. The 2-year pilot project was 
supported and conducted in collaboration with the National 
Institutes of Health’s National Heart, Lung, and Blood Institute 
(NHLBI). 
Overall project goals included determining the number of 
people with SCD and thalassemia and increasing knowledge 
and awareness about health care use and outcomes. Seven 
states were funded to participate in data collection: California, 
Florida, Georgia, Michigan, New York, North Carolina, and 
Pennsylvania. Due to the unique nature of the available data 
sources in each state, a variety of data collection methods were 
employed.
It is anticipated that these state-based surveillance data will:
 y Provide estimates of the number of new cases (incidence) of 
SCD and thalassemia each year. 
 y Provide estimates of the total number of existing cases 
(prevalence) of SCD and thalassemia.
 y Provide information on trends in medical care for people 
with these disorders.
 y Provide information about complications and death rates.
 y Provide information to assist with planning public health 
interventions (i.e., services, health promotion campaigns, 
health education, and training) to improve the health of 
these populations.
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Strategy Field Reports
The purpose of this document is to showcase the unique ways 
in which the states implemented activities designed to meet 
the programmatic goals of RuSH. In the following sections, each 
state highlights a particular aspect of its data collection process, 
including information about the resources needed to operate 
or replicate the activity and lessons learned. The intent is to 
give a brief overview of the complexity of this project and to 
provide contact and programmatic information to other entities 
for the potential modification or replication, or both, of activities. 
The information in this report was provided by programmatic 
team members who worked with CDC staff in spring 2012.
Case Definition
An important initial step in developing the RuSH pilot project 
was defining the patients with hemoglobinopathies that 
were included in the surveillance efforts. Because most of the 
collected information came from preexisting data sources, 
and these data sources varied greatly among the seven states, 
a case definition was created to help standardize the studied 
population as much as possible. A workgroup consisting  
of clinicians and public health professionals was established 
to help CDC and the NHLBI in creating the definition. Please 
note that this definition and its corresponding complications, 
procedures, and treatments will be referred to throughout  
this document.
LEVEL 1: HIGH
 y Results of a state newborn screening program with 
confirmatory testing, or 
 y Clinical diagnosis by a physician with documented 
confirmatory laboratory testing after the newborn period.
LEVEL 2: PROBABLE 
 y Results of a state newborn screening program without 
confirmatory testing, or 
 y Hemoglobinopathy-related International Classification of 
Disease (ICD) -9 or -10 code (see following codes; excluding 
sickle cell trait) used during two or more separate health 
care encounters, plus one or more hemoglobinopathy-
associated complication, treatment, or procedure (see 
following lists)
LEVEL 3: POSSIBLE
 y Sickle cell trait ICD -9 or ICD-10 code (see following 
codes) used during two or more separate health care 
encounters, plus one or more hemoglobinopathy-associated 
complication, treatment, or procedure (see following lists ), 
or
 y Single health care encounter with a hemoglobinopathy-
related ICD -9 or ICD-10 code(see following codes; excluding 
sickle cell trait)
*Health care encounter: Inpatient or outpatient hospitalization or health care visit, including emergency department visits. 
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Hemoglobinopathy-Related 
International Classification of 
Disease (ICD) Codes
ICD-9  Codes
282.4  Thalassemias
282.41  Sickle cell thalassemia without crisis
282.42  Sickle cell thalassemia with crisis
282.49  Other thalassemia
282.6  Sickle cell disease
282.5  Sickle cell trait
282.60  Sickle cell disease, unspecified
282.61  Hb-SS disease without crisis 
282.62  Hb-SS disease with crisis
282.63  Sickle cell/Hb-C disease without crisis
282.64  Sickle cell/HB-C disease with crisis
282.68  Other sickle cell disease without crisis
282.69  Other sickle cell disease with crisis
ICD-10  Codes
D56  Thalassemia 
D56.0  Alpha thalassemia 
D56.1  Beta thalassemia 
D56.2  Delta-beta thalassemia 
D56.8  Other thalassemias 
D56.9  Thalassemia, unspecified 
D57  Sickle cell disorders 
D57.0  Sickle cell anemia with crisis 
D57.1  Sickle cell anemia without crisis 
D57.2  Double heterozygous sickling disorders 
D57.3  Sickle cell trait 
D57.8  Other sickle cell disorders 
Hemoglobinopathy-Associated 
Complications
1. Chronic renal failure/Proteinuria
2. Pneumonia, acute chest syndrome
3. Pulmonary hypertension 
4. Stroke (ischemic or hemorrhagic), transient ischemic attack, 
seizures 
5. Intracranial bleeding
6. Priapism 
7. Iron overload 
8. Gallstones/cholelithiasis, cholecystitis
9. Avascular necrosis
10. Retinal disease
11. Splenomegaly, splenic sequestration, hypersplenism 
12. Leg ulcers
13. Dactylitis
14. Osteomyelitis
 Hemoglobinopathy-Associated 
Treatments
1. Hydroxyurea
2. Parenteral analgesics
3. Iron Chelators
4. Erythropoietin
5. Folic acid
Hemoglobinopathy-Associated 
Procedures
1. Red cell transfusion
2. Red cell exchange
3. Splenectomy
4. Cholecystectomy
5. Transcranial Doppler 
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North Carolina:  
Matching Existing Government and Clinical Datasets
Program Overview
The goal of the North Carolina (NC) RuSH project was to 
identify the number of people with sickle cell disease (SCD) 
or thalassemia who received care and services in North 
Carolina during the years 2004–2008. A secondary goal was 
to determine what health services this population received 
during the same timeframe. Specifically, the NC RuSH project 
was designed to collect information from specific datasets from 
various governmental and clinical data sources. The existing 
datasets included information on demographics, clinical 
diagnoses (i.e., laboratory test or International Classification 
of Disease, 9th Revision or 10th Revision), mortality, health 
care use, medical complications, procedures, and treatment 
modalities. 
This surveillance effort supports North Carolina’s commitment 
to ensure that people living with SCD or thalassemia lead an 
independent, healthy life. Moreover, the gathered surveillance 
data will guide the health practices for program partners 
and health care professionals, to better serve populations 
affected by hemoglobinopathies. Ultimately, this will increase 
the knowledge and awareness of SCD and thalassemia for 
stakeholders, policy makers, and residents of North Carolina. 
In addition, it will ensure the best use of allocated resources 
for the North Carolina Division of Public Health’s Sickle Cell 
Syndrome Program (NCSCSP) and better streamline educational 
and outreach strategies. 
Resources Needed:
To successfully conduct statewide surveillance of people  
with SCD or thalassemia, it was critical to determine the 
systems within state government that provided access to 
information on the targeted populations and attain legal 
access to these systems. In particular, letters of agreement 
or memorandums of agreement, or both, were established 
with various governmental agencies, clinical partners, and 
community entities to capture patient data. Following is a list  
of agencies with which agreements were established to 
facilitate the project: 
6. North Carolina Women’s and Children’s Section Web-based 
System (WCSWeb)—NCSCSP client data
7. North Carolina State Center for Health Statistics—hospital 
discharge, Medicaid, and birth and death records
8. North Carolina Disease Event Tracking and Epidemiologic 
Collection Tool (NC DETECT)—emergency department data
9. North Carolina Purchase of Medical Care Program 
(POMC)—state program insurance claims data
10. North Carolina Immunization Registry (NCIR)—vaccination 
data
11. North Carolina State Laboratory of Public Health (SLPH—
newborn and nonnewborn data
12. North Carolina Comprehensive Medical Centers—six 
comprehensive sickle cell centers’ client data
13. University of North Carolina at Greensboro—data analysis 
and evaluation
Other resources included staff with specific skill sets, such 
as information technology (IT), programmers/coders, data 
managers, program coordinators, and epidemiologists. Time 
required for data coordination was substantial, as 75%–100% 
of the time of one FTE was needed. There also needed to 
be consideration for the availability of appropriate computer 
software and hardware such as SAS, SPSS, and Microsoft® Excel 
2010 to extract, deduplicate, and link data. Budget cost can be 
significant if the skill sets and other technology are not readily 
available. It is advisable to use in-kind services when possible to 
offset cost. These resources were essential for matching existing 
datasets within surveillance systems.
Lessons Learned:
Goals and objectives need to be clearly defined at the onset of 
the project; changes in these can affect the project and cause 
delays, as well as increase cost and resources. There must be 
adequate time allowed so that all partners are able to agree on 
deliverables and clearly define the expectations for the work. If 
competing agendas and issues of data privacy arise, these may 
challenge the prioritization of surveillance activities. There is a 
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chance that substandard data may be delivered, so this  
will require additional review and analysis. Validation of 
the quality of the data is necessary. Finally, if only limited 
information is available from the datasets requested from 
participating partners, this may inhibit the matching of 
data among data sources. 
Outcome:
Preliminary findings identified approximately 8,955 unique 
individuals with sickle cell disease or thalassemia who were 
living in North Carolina during the years of 2004–2008. 
Roughly 50% were Level 1 cases, 14% were Level 2 cases, and 
36% were Level 3 cases. Analysis of these data allowed public 
health officials to derive prevalence and incidence estimates of 
hemoglobinopathies in North Carolina, as well as the effects of 
these diseases. 
Data collection for this activity provided opportunities 
in the enhancement and evaluation of the NCSCSP. It 
benefitted patients, health care providers, community-based 
organizations, faith-based communities, policy makers, and the 
general public. This type of information helped to determine 
quality of care standards, service delivery, and resource 
distribution. In addition, it created a road map and model for 
accessing data and building interagency collaboration within 
state government. The final analysis of the data provided 
information and best practices to: 
1. Outline a clear plan and approach for improved medical 
treatment, services, and resources.
2. Make a case for continued support of the program.
3. Direct efforts to targeted populations with the greatest need.
4. Shape the development of health promotion messages 
and outreach strategies.
5. Increase knowledge of general public.
6. Track trends of the effects of these conditions on 
individuals throughout their lifespan. 
Sustainability/Translation:
The NCSCSP is committed to advancements in the treatment, 
research, legislation, and quality of care for people with SCD 
or thalassemia, which ultimately might lead to a cure for these 
diseases. The RuSH project laid a foundation and framework 
to provide a global platform to address hemoglobinopathies 
at a level that examines the diseases beyond diagnosis and 
treatment. The NC RuSH effort will continue to advocate 
and seek resources and opportunities to build a registry for 
hemoglobinopathies. Efforts that will continue beyond RuSH 
funding include sharing of interagency data, enhancement of 
SLPH with the WCSWeb and building of statewide partnerships. 
The surveillance for hemoglobinopathies provides a model 
to investigate the trends and epidemiology of other health 
conditions as well, such as heart disease, stroke, or Alzheimer 
disease. The NC RuSH project could serve as a model for 
all areas of health care to ensure that work being done is 
adequate to address the needs of the community affected by 
hemoglobinopathies and is based on sound data and practices. 
This work is translatable to other areas of public health because 
it sets a standard and is an impetus for surveillance. Surveillance 
for hemoglobinopathies should be a basic public health activity 
to ensure that the appropriate protocols, treatments, and 
prevention efforts are being provided at the federal, state, and 
local levels.
Contact Information
Yvonne Greene
Yvonne.Greene@dhhs.nc.gov 
919-707-5717
www.ncsicklecellprogram.org 
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Georgia:  
Limitations of International Classification of 
Disease (ICD) Codes for Defining and Identifying 
Hemoglobinopathy Cases
Program Overview
Each of the RuSH states used International Classification 
of Disease (ICD) codes to identify people with 
hemoglobinopathies in at least one administrative dataset. 
States also used the ICD ninth or tenth revision (ICD-9 or ICD-
10) codes to classify mortality data from death certificates and 
the International Classification of Diseases, Clinical Modification 
(ICD-9-CM or ICD-10-CM) codes to classify morbidity data 
from inpatient and outpatient records, public and private 
health insurance claims, and public health programs. 
While several subcategories of ICD codes were available to 
distinguish between different types of hemoglobinopathies, 
the coding for clinically relevant types of hemoglobinopathies 
in administrative datasets might not always be specific. 
Therefore, ICD codes for common comorbid conditions were 
sought in hospital discharge and billing data from public and 
private insurance programs and used to add specificity to case 
classification, along with Current Procedural Terminology® 
(CPT®) and National Drug Codes (NDC) for common medical 
procedures and treatments found in outpatient and pharmacy 
billing data.
Resources Needed
Identification of hemoglobinopathy cases in Georgia was a 
team effort, as much of the administrative data necessary 
for the surveillance project were not within the purview of 
Public Health. Thus, the project required partnerships and 
data-sharing agreements between Public Health and the 
state Medicaid/Children’s Health Insurance Program (CHIP) 
agency, as well as the entity that collects, standardizes, and 
manages the state’s hospital discharge data, the Georgia 
Hospital Association (GHA), a nonprofit trade organization. It 
was necessary for Public Health and the Georgia RuSH team 
to acquire identified, person-level data from these partners. In 
return, partners were assured that the data would be secured 
and the process would adhere to all Health Insurance Portability 
and Accountability Act protections. Georgia also had a benefit 
in this effort, as both sickle cell disease (SCD) and thalassemia 
are reportable conditions for children up to 18 years of age 
through surveillance for birth defects. Mining, coding, and 
deduplicating each of the datasets required the expertise of 
at least a part-time data analyst comfortable working with 
large administrative datasets. In addition to the data analyst, 
the principal investigator and Public Health representative also 
devoted significant personnel time to securing necessary data-
sharing agreements. 
Lessons Learned
Administrative data are collected for billing purposes, not 
surveillance or research. Many individual records had several 
ICD codes listed because the provider considered them as 
possible diagnoses, even if those diagnoses later were ruled 
out. Therefore, it was important to look for more than one 
instance of a particular diagnosis when attempting to count 
true cases of disease. 
Case comparison across datasets was limited due to the lack of 
consistency in ICD coding for the hemoglobinopathy-related 
complications, treatments, and procedures used in the RuSH 
case definition. For example, while hospital discharge and 
billing data provided evidence for complications via ICD codes, 
only outpatient billing data supplied CPT® and NDC to identify 
medical procedures and treatments.
ICD codes were better at identifying SCD than thalassemia 
because there were codes for subcategories of SCD, including 
a code for sickle cell trait. There was only one category for 
thalassemia in the ICD-9 classification and it did not distinguish 
between thalassemia trait and thalassemia disease. 
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It was possible to create a surveillance system with 
administrative data and it was determined that datasets with 
better unique patient identifying information were more 
favorable for matching and deduplication purposes. In the 
absence of unique identifiers like social security numbers, many 
assumptions needed to be made and deduplication took a 
significant investment of time.
Outcome
The Georgia RuSH team was able to use the individual-level 
hospital discharge data to show the frequency of emergency 
department (ED) visits and inpatient stays in each county, and 
to characterize disease prevalence by age group, sex, race 
and ethnicity, and county of residence. This information was 
provided in poster form to sickle cell support groups around 
the state for use in their outreach and advocacy efforts. 
Findings reinforced community experience regarding areas of 
the state with the greatest disease burden, the needs of youth 
transitioning to adult care, and the nature of hospital spending 
on hemoglobinopathy-related care. Better prevalence data 
now can be shared with partners. For example, the percentage 
of patients with SCD covered by Medicaid can be estimated. 
Medicaid claims data also can be used to evaluate the frequency 
and type of care that patients with hemoglobinopathies receive 
to help target provider education efforts.
Sustainability/Translation
Additional funding is necessary to design and complete 
validation studies that determine the accuracy of the RuSH 
case definition. That is, what percentages of Level 2 and Level 
3 cases actually have a hemoglobinopathy? Without additional 
funding, it also will not be possible to define and identify 
additional hemoglobinopathy cases outside of the study 
period. One sustainable activity will be the use of administrative 
data to advance the knowledge of health service use by 
individuals with hemoglobinopathies. 
This project can help to inform surveillance activities for 
other noninfectious, chronic conditions that affect individuals 
throughout their lifetime. In Georgia, a first step would be 
to approach the GHA and state Medicaid agency about 
reporting all birth defects of children up to 8 years of age. 
While birth defects currently are reportable in Georgia, the 
system is passive and reporting compliance is low. Insurance 
or provider organizations, or both, could provide a service for 
their members by periodically searching their administrative 
databases for specific ICD codes and reporting cases to the 
Public Health Department.
Contact Information
Brendan Noggle, MPH
rbnoggle@dhr.state.ga.us 
404-463-2099
12
RuSH—Strategies from the Field: Data Collection
California:  
Obtaining and Using Medicaid Data for 
Hemoglobinopathy Surveillance
Program Overview
California’s focus in the RuSH project has been to identify 
as many cases as possible of sickle cell disease (SCD) and 
thalassemia using administrative and clinical data. Using 
the methodology and case definitions developed by the 
seven funded states and the Centers for Disease Control and 
Prevention, over 5,800 confirmed or probable cases of SCD 
were identified in the state in 2008, which represents over 90% 
of the estimated number of cases based on extrapolations of 
case count from demographic data.1 Additionally, over 1,000 
confirmed cases of alpha or beta thalassemia were identified in 
2008, and algorithms are being developed to better determine 
probable cases from the data.
Obtaining administrative and clinical data to do this work 
was successful. Access was granted to (1) newborn screening 
data going back as far as 1999; (2) all electronically available 
hospital discharge and emergency room visit data and vital 
records (birth and death certificates); and (3) data for patients 
with SCD or thalassemia attending clinics at the Children’s 
Hospital & Research Center Oakland and Children’s Hospital Los 
Angeles (both have adult SCD and thalassemia clinics, as well 
as pediatric clinics). In addition, Medi-Cal (California’s Medicaid 
system) data related to members with one or more SCD- or 
thalassemia-related International Classification of Disease,  
(ICD-9) codes was made available.
Medi-Cal data were the most difficult data to obtain and to 
work with; however, while each of these sources was vital in 
helping identify cases or contributing key information about 
cases found, or both, Medi-Cal data contained the greatest 
number of cases not seen elsewhere and the most information 
about cases seen. 
Resources Needed
California RuSH employed two full-time staff: a project 
director/epidemiologist responsible for obtaining data from 
agencies and clinics and a database developer who managed 
and cleaned all datasets, developed matching algorithms 
across them, and linked and deduplicated the cleaned data. 
California’s Department of Health Care Services (DHCS) is the 
agency responsible for the Medi-Cal program, and data were 
requested directly from it for this project. The state’s Committee 
for the Protection of Human Subjects declared the RuSH 
project to be a nonresearch surveillance activity prior to the 
contract being established with the DHCS; however, the DHCS 
required a review and approval by its own Data and Research 
Committee before granting access to data. This review was a 
multistep process in which the RuSH project staff requested 
particular variables, such as social security numbers, patient 
ZIP Codes, and exact dates of birth from all claims related to 
individuals who had one or more SCD- or thalassemia-related 
ICD-9 codes during the period 2000–2008. The committee 
approved, denied, or requested more information on the 
justification for each variable. Approval took over 6 months, 
while transfer of the initial data set took an additional 4 months 
from approval to receipt.
Once the initial dataset was received from the DHCS, it was 
compared to the datasets already received from other agencies 
and clinic partners, and a list of cases seen in the other 
sources—but not in the Medi-Cal data—was created. That 
list was sent to the DHCS with a request to pull all claims seen 
for those individuals as well; this request was granted quickly. 
Once all data were received, weighted matching algorithms 
were developed to enable linking and deduplication of data 
using social security numbers. When linking had taken place, 
work with the claims themselves was begun. Because this 
data source had not been developed with an eye toward 
research or surveillance (as in the case of hospital discharge 
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data, for example), extensive data cleaning and translation 
were necessary. Five different billing code systems were 
used (e.g., International Classification of Disease, 9th Revision; 
Current Procedural Terminology®; and Healthcare Common 
Procedure Coding System) in one variable, and these needed 
to be standardized. Some identified cases had two distinct 
identification numbers: some claims were located by social 
security number, while others were found using a county-
specific Medi-Cal identifier. Rather than receiving cleaned data, 
the RuSH team received a data file that included all claim “lines”; 
because of this, many of the encounters in the claims data were 
entered multiple times to account for claim corrections and 
resubmissions. These duplicate entries were accounted for in 
analyses involving counts of visits or claims or dollar amounts. 
Solving these problems was one of the most time-consuming 
elements of the RuSH project. 
Lessons Learned
States using Medicaid data for disease surveillance would be 
advised to recognize the differences between that data source 
and other administrative data sources. For example, hospital 
discharge data produced at the state level can be a research- 
or surveillance-ready product, with variables cleaned and 
well explained in a data dictionary. Budgeting extra time for 
obtaining and working with the data is advised. Additionally, 
should an “eligibility file” describing when members’ eligibility 
for benefits began and ended be available, states are advised 
to request that information. Such files allow the analysis of 
Medicaid members as a cohort with appropriate censoring 
dates. 
Outcome
Despite challenges, Medi-Cal data were found to be well 
worth the time and effort to the project. In the case of SCD, an 
estimated 545 (14%) of 3,901 probable cases were identifiable 
only through the Medi-Cal record, a much greater proportion 
than from any other single data source, and 3,958 (64%) of 
6,208 confirmed and probable SCD cases had data in the 
Medi-Cal file. Similarly, among the 1,920 probable cases of 
thalassemia, 287 (15%) were seen only in the Medi-Cal data, 
and 6,194 (38%) of the 16,504 probable or possible cases were 
seen in the Medi-Cal data. Additionally, all information about 
outpatient services and prescription treatments for identified 
cases came from this source. 
Sustainability/Translation
California currently is seeking other funding sources to continue 
surveillance of hemoglobinopathies and looking toward the 
development of an ongoing patient registry. While there is no 
funding in place to continue the collection of administrative 
or clinical data, the CA RuSH team is optimistic that the utility 
of the work done to understand the public health implications 
of hemoglobin disorders among the state’s population will 
lead to funding for continued work. In addition to establishing 
a baseline count and understanding of the effects of SCD 
and thalassemia among the population, this work has set the 
stage for the use of administrative and clinical data to conduct 
surveillance for other genetic disorders.
The use of Medicaid claims data in conjunction with other data 
sources can be a powerful tool in public health surveillance, 
allowing both effective case identification and an abundance 
of information on complications, treatments, and outcomes for 
the cases, including outpatient and prescription information 
not readily available via other administrative data sources. 
Obtaining and working with the data were not straightforward, 
but the data’s utility more than made up for the difficulties in 
gaining access to it.
References:
7. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The 
number of people with sickle-cell disease in the United 
States: national and state estimates. Am J Hematol. 2010 
Jan;85(1):77–8. PubMed PMID: 20029951. 
Contact Information
Lisa Feuchtbaum, DrPH, MPH
lisa.feuchtbaum@cdph.ca.gov
510-412-1455
www.casicklecell.org
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Pennsylvania:  
The Use of Partnerships in Creating a 
Hemoglobinopathy Database
Program Overview
The Pennsylvania Department of Health (PA DOH) developed 
a linked data surveillance system for patients with sickle cell 
disease (SCD) or thalassemia in Pennsylvania. Due to privacy 
issues that could not be resolved within a reasonable time 
frame, the PA DOH could not obtain data from vital statistics, 
Medicaid, or the Pennsylvania Health Care Cost Containment 
Council’s (PHC4) hospital discharge database. As a result, the 
PA DOH established a partnership with the three leading 
childrens hospitals in Pennsylvania: St. Christopher’s Hospital 
for Children, The Children’s Hospital of Philadelphia® (CHOP), 
and Children’s Hospital of Pittsburgh (CHIP) to aggregate 
descriptive data about their respective populations with SCD 
and thalassemia, as well as Carnegie Mellon University (CMU) 
to provide analytical support for de-identifying, cleaning, and 
linking the databases. The databases used to link the newborn 
screening dataset to the vital statistics data were the hospital 
administrative databases from the previously listed hospitals. 
These databases were created to incorporate data specific to 
patients with SCD or thalassemia. These datasets contained 
the data elements that were decided on by the RuSH Data 
and Harmonization workgroup. Fine-grained Record Linkage 
software was used to link all of the databases used in this 
project. The individuals on the RuSH team from each of the 
three childrens hospitals negotiated with the information 
technology department at their respective facilities to create 
a dataset of patients with SCD or thalassemia who met the 
criteria set up by the workgroup.
Resources 
Each institute brought its own unique qualities to this 
partnership. The PA DOH provided the newborn screening 
database to the partnership and the staff to assist in the 
coordination of the development of the linked database. The 
hospitals each brought a wealth of data about its patients 
with SCD or thalassemia who currently were being treated or 
had been treated in the past. CMU brought in the computer 
resource and de-identification technologies, database 
management, and data linkage expertise to the partnership. 
Coordinating the process of creating the database required 
frequent conference calls with the partners, and time and effort 
dedicated to the project beyond that spent tracking patients 
and completing usual duties. 
CMU’s Management Science & Healthcare Informatics 
research group was instrumental in supporting the project 
through its expertise in data privacy, cleaning, and linkage. 
It was absolutely necessary to have the group’s expertise 
to harmonize all of the data sources. Because all of the data 
already existed within the three childrens hospitals and the PA 
DOH, there were no costs incurred to obtain the data.
Lessons Learned:
Working with partners to establish timelines for data 
submission can be a very challenging process, especially when 
integrating numerous sources of data from different software 
platforms and dealing with different institutional policies 
and practices. Allowing for plenty of time and flexibility to 
discuss and resolve any problems that arise in the process is 
essential. Assembling the appropriate teams with expertise 
in the clinical domains; epidemiology and public health; 
information technology as applied to health care data and 
resources; analytic capabilities and project management; and, 
most importantly, knowledge of and links with the target 
community of patients with SCD also is essential to the success 
of such projects. One of Pennsylvania’s limitations regarding 
this database was that data that were related to the adult 
population who had SCD or thalassemia were not included. 
Future collaborations will be able to obtain data related to 
adults with these diseases. 
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Outcomes
The formation of a partnership that was integral in 
accomplishing the construction of a hemoglobin database 
containing data from three separate treatment facilities and 
PA DOH’s newborn screening database was a tremendous 
accomplishment for the state. Participating in this process 
provided a close to accurate account of the population 
of people with SCD or thalassemia living in Pennsylvania, 
especially the pediatric population, and the service use 
of treatment centers and community-based organization 
resources that are funded through contract agreements with 
the state. A stronger foundation to assess resource needs for 
the populations with SCD and thalassemia also was established. 
From the International Classification of Disease, Revision 9 
codes included in the database from each hospital, the PA 
RuSH team was able to translate these codes into the types of 
hospital services that were used by the pediatric population 
with SCD. This information then can be translated into actual 
dollars that can be used in a cost analysis (i.e., actual cost of 
average admission vs. insurance reimbursement; average cost 
of fever admission vs. reimbursement).
The PA DOH now has a more accurate snap shot of the 
populations with SCD or thalassemia in Pennsylvania. There 
also is a better understanding of the data linkage methods and 
mechanisms needed to aggregate statewide data about service 
use and resources needed for specific diagnosis groups. As a 
result of the work of the partnership, it will be possible to create 
a data hierarchy that can be used as a tool to determine what 
information or data are most helpful in understanding specific 
population needs. 
As grantees of the PA DOH Sickle Cell Service grant, the CHOP, 
CHIP, and sickle cell hemoglobinopathy centers (SCHC) are 
required to provide quarterly reports to demonstrate sickle 
cell management and psychosocial service use. Through 
participation in RuSH, it was recognized that the existing 
reporting template could be modified to provide a more 
comprehensive snapshot of the patient population with SCD, 
and its service and resource use in the state of Pennsylvania. 
More specifically, the process of compiling surveillance data 
presented an opportunity for the PA DOH and its grantees to 
revisit current quarterly reporting fields and assess whether 
the right questions were being asked to determine service and 
resource use and create a data hierarchy as a tool to address 
specific circumstances (e.g., addressing populations needs or 
allocating funds). The data collection process also has led to the 
increase of statewide understanding of the populations with 
SCD or thalassemia and the associated service use data. 
In addition, the process has emphasized the need to store 
newborn screening information and to maintain hospital 
system disease-specific databases until more innovative 
information technology systems are available. This also will help 
guide or modify the information collected for quarterly state 
reporting and answer questions such as: Are the appropriate 
data being provided or do modifications need to be made? 
Pennsylvania also is well positioned to conceptualize and 
develop a statewide registry for SCD and thalassemia that can 
build on the integrated solution developed for the current 
effort. RuSH objectives that were accomplished from this data 
linkage project included collaboration, by involving appropriate 
within-state partners, and data integration, by linking 
information from the three childrens hospitals, the PA DOH’s 
newborn screening data, and the state’s vital records.
Sustainability/Translation
While the PA RuSH team has been successful in obtaining data 
from three hospitals catering to the needs of a large number of 
children with hemoglobinopathies, gaps in surveillance remain. 
Ongoing efforts to secure data user agreements between 
the DOH, PHC4, and Department of Public Welfare (DPW) 
will enable these data to be linked. Meetings with the DPW 
concerning these issues currently are under way. Discussions 
with the PHC4 will take place in the near future.
The establishment of these partnerships hopefully will serve as 
a model to expand the surveillance program to include other 
hospitals in Pennsylvania, as well as information on the adult 
population with SCD or thalassemia. Successful integration of 
data from the PHC4 and the DPW would enhance greatly efforts 
to accomplish this model surveillance program goal.
Contact Information:
William Cramer, MEd
wcramer@pa.gov
717-783-8143
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Florida:  
Creating a Physician Reporting Website
Program Overview
Members of the Florida RuSH team, designed a website that 
allows physicians throughout the state to submit laboratory 
confirmed sickle cell disease (SCD) and thalassemia patient 
information, including personal identifiers such as name, social 
security number, date of birth, home address, place of birth, 
sex, race, and ethnicity for accurate linking of multiple source 
datasets used in the RuSH project (hospital discharge data, 
vital statistics, Children’s Medical Services, Memorial Healthcare 
System, and Medicaid) and to aid in case confirmation. The 
website is completely secure and entered data is accessible 
only by Florida Department of Health staff. A physician creates 
a profile and is assigned a site identification number. Physician 
support staff can create a subaccount linked to the physician for 
purposes of entering data on the physician’s behalf. To ensure 
the accuracy of data input by staff, the physician logs into the 
website to review and confirm data that then are transmitted to 
Florida Department of Health staff. 
Clinicians with the highest volume of patients were identified 
through the hospital databases and subsequently contacted by 
our team, who encouraged them to enter SCD and thalassemia 
patient data into the website. Physicians identified through 
churches and social groups were also invited to enter data. In 
addition, the Cooley’s Anemia Foundation was contacted, and 
responded with a list of physicians in Florida who provide care 
to individuals with thalassemia.
Resources Needed
The creation of a physician reporting website required the 
support of an experienced Web designer. Discussions with 
staff knowledgeable in health informatics, record linkage, and 
epidemiology, as well as with physicians, also were needed 
to define the types and formats of the data to be collected. 
Using the recommendations provided during these discussions, 
the website was designed and built. Furthermore, a list of 
physicians who provided confirmatory testing for the state 
newborn screening program and clinicians with high volumes 
of patients with SCD or thalassemia was essential to target the 
appropriate physicians to provide data. Financial incentives of 
$25 per patient record entered were offered to each physician 
to offset the time and effort required on their part. 
Lessons Learned
The biggest hurdles we overcame in the creation and 
implementation of a physician reporting website were 
understanding the challenges of a physician’s busy practice 
and identifying dedicated staff to enter data. Data were entered 
when staff had an opportunity to do so. It was essential 
to identify the person in the physician’s office who was 
responsible for this task and work directly with him or her to 
facilitate the process or suggest to the physician bringing in an 
outside person for the project.
Outcome
The physician reporting website was launched in February 
2012. Technical support was provided to sites and the first 
data entry began in April 2012, with 120 inputs in the first 48 
hours. A total of 159 cases have been reported since then. 
The highest volume (53.21%) of cases was represented by 
hemoglobin SS (HbSS) . There were 6 cases of thalassemia and 
12 cases reported as “Other Variant” as the diagnosis, including 
persistent fetal hemoglobin, Diamond Blackfan anemia, HbSN 
Baltimore, and HbCC.  
Sustainability/Translation
Results of specific physician-reported cases can be shared with 
the reporting physician and aggregate data can be shared 
with all physicians caring for this patient population to observe 
the course of a disease, to understand variations in treatment 
and outcomes, to examine factors that influence prognosis 
and quality of life, and to describe care patterns, including 
appropriateness of care and disparities in the delivery of care. 
It is unlikely that the Florida RuSH project activities will be 
sustained without continued extra-mural funding. The budget 
situation for state government in Florida continues to require 
scaling back of vital programs and services, and very few new 
programs have been funded in the past three years. While 
we plan to utilize the results of the RuSH project for health 
education activities and will continue to work with providers 
as well as support groups, without funding for data acquisition, 
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linkage and integration, and analysis, the surveillance portion of 
RuSH will likely not continue unless a new funding mechanism 
is obtained.
Moving forward, the approach utilized by the Florida RuSH team 
has potential to extend to a number of other genetic disorders 
and health conditions that pose continual challenges to those 
affected across their lifespan. Our model that included public 
health, epidemiology and informatics, clinician leaders, and 
outreach seems well suited to tracking other conditions and could 
be useful for other rare disorders and blood-related diseases.
Contact Information:
Mary Beth Vickers, RN, MSN
Marybeth_vickers@doh.state.fl.us
850-245-4222 
www.cms-kids.com
Michigan:  
Creating a Statewide Hemoglobinopathy  
Long-Term Follow-Up Module
Program Overview 
Since 1987, children identified with sickle cell disease (SCD) 
through Michigan’s Newborn Screening Program have been 
followed from birth through 5 years of age by the State 
of Michigan. To provide more comprehensive follow-up 
through the lifespan, Michigan recently developed a Web-
based hemoglobinopathy follow-up module in the already 
established Michigan Care Improvement Registry (MCIR). 
The hemoglobinopathy MCIR application allows for improved 
programmatic communication and invaluable information for 
hemoglobinopathy surveillance. The primary objective was to 
develop a Web-based follow-up module to monitor:
8. Diagnosis of all newborns referred with positive screening 
results for SCD. 
9. Initiation of penicillin prophylaxis. 
10. Hemoglobinopathy education and social work services. 
11. Self-reported complications, screenings, and treatments 
related to SCD.
Resources Needed
Michigan birth records have been linked with newborn 
screening records since 2007. This linkage is completed 
weekly in the Division of Genomics, Perinatal Health, and 
Chronic Disease Epidemiology at the Michigan Department 
of Community Health using Link Plus software to identify 
potentially unscreened infants. Cases are matched using birth 
certificate identifiers and other unique information such as the 
infant’s name, mother’s name, and infant’s date of birth. All 
linked records are uploaded weekly into the MCIR and profiles 
for children with abnormal hemoglobinopathy screening results 
are created automatically in the MCIR hemoglobinopathy 
module with newborn screening results determining the 
default case diagnosis. 
Computer programmers with a background in the 
immunization components of the MCIR were tasked with 
the design and creation of a customized MCIR module for 
hemoglobinopathies. Follow-up duties (e.g., tracking status 
of penicillin prophylaxis and documenting home visits and 
telephone calls) were integrated into the application based 
on already established follow-up protocols in collaboration 
with the Sickle Cell Disease Association of America, Michigan 
Chapter (SCDAA-MI). In Michigan, the SCDAA-MI is responsible 
for provision of comprehensive services to all newborns 
with hemoglobinopathies detected by newborn screening. 
Data fields were established and approved by Michigan’s 
Hemoglobinopathy Quality Improvement Committee, an active 
group of pediatric and adult hematologists practicing across 
the state. Data fields include: newborn screening laboratory 
results, confirmatory test results, penicillin prophylaxis start 
dates, ongoing status of prophylaxis through age five, and 
self-reported health status information, including demographic 
variables and barriers to care. 
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Lessons Learned:
Development and acceptability of a Web-based MCIR 
hemoglobinopathy module was successful as a result of 
significant time, staff, and funds expended specifically for this 
project. Replication of the module might be challenging for 
other institutions due to both the infrastructure and resources 
that are required for implementation. Building a similar module 
with fewer interactive and automated mechanisms still could 
serve as an effective surveillance tool without full-scale 
integration of every follow-up, communication, and reporting 
activity. In Michigan, this Web-based registry proved extremely 
useful for communication across different communities and 
allowed for health results and concerns to be identified in real 
time. This Web-based component also will be essential for 
any future integration of this module in sickle cell clinics by 
hematologists. 
Outcome:
Regional patient advocates working for the SCDAA-MI have 
been documenting all follow-up activities for their clients in 
the hemoglobinopathy MCIR module since January 2011. Case 
profiles also are being created continually for older clients 
with SCD, with the goal of having baseline information for 
all patients with SCD from birth through 25 years of age in 
the MCIR by 2013. Data from the module will be included 
in a comprehensive surveillance and data report on SCD 
in Michigan, future educational campaigns, and potential 
advocacy initiatives. Michigan will continue to validate the 
data through a link between health status assessment findings 
and Medicaid claims. The health status assessment findings 
will provide valuable feedback to Michigan’s hematologists, 
serve as the basis for adapting clinical protocols, and 
stimulate future research and program initiatives in Michigan’s 
hemoglobinopathy quality improvement committee. 
Sustainability/Translation:
A transition will take place during the final 6 months of RuSH 
funding, changing the title of this self-reported data collection 
initiative to “Sickle Cell Voices”. Ongoing feedback will be used 
for quality improvement measures as questions are revised and 
adapted in the coming year. With enough momentum behind 
the hemoglobinopathy MCIR module, further completion of 
health status assessments and tracking of routine follow-up 
through the MCIR will continue past the end of the RuSH 
project. The Michigan Newborn Screening Program is in a 
secure position to fund troubleshooting and technical support 
to ensure that the application continues to be used to its fullest 
capacity. Newborn screening staff will monitor data collection 
for quality assurance, creating periodic briefs and reports. 
Applications for future data analysis will endure as surveillance 
information from the hemoglobinopathy MCIR module 
continues to grow with time. 
Contact Information:
William Young, PhD
517-335-8938
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New York:  
Case Ascertainment of Individuals With 
Hemoglobinopathies Not Identified Through 
Newborn Screening
Program Overview:
As a result of newborn screening (NBS), all babies born in 
New York State (NYS) since 1975 have been screened for 
hemoglobinopathies. However, individuals born before 
screening began, in another country, in another state, or 
outside of a hospital setting are not in the NBS database. 
Therefore, such individuals must be sought out to provide 
the most accurate count of people living in NYS with these 
disorders, as well as available clinical information related to 
those individuals. 
To identify such cases, letters were sent to providers at 31 
pediatric hemoglobinopathy specialty care centers (HgbSCCs) 
informing them about the RuSH project and asking for them 
to participate in clinical data review of any patients seen and 
treated at their centers during the period 2004–2009. Those 
centers interested in participating in RuSH were sent copies 
of the project protocol, the executive summary, a list of data 
elements to be collected, and a copy of the NYS Department of 
Health’s Institutional Review Board (IRB) approval of the project. 
Due to Health Insurance Portability and Accountability Act 
(HIPAA) privacy laws concerning individually identifiable health 
information, all RuSH project tasks concerning collection of 
personally identifiable information were subject to review and 
approval by each institution’s IRB. Follow-up was conducted 
with each of the providers by telephone or email, or both, 
over the next several months to guide interested providers 
in submitting protocols to each of their IRBs prior to moving 
forward with data review. 
In addition, a letter from the NY State Commissioner of Health 
was sought to give the RuSH principal investigators the 
authority to collect data on patients with hemoglobinopathy 
for the purpose of establishing a patient registry. As a result, an 
order was issued under Public Health Law 206 (1)(j) in January 
2012 doing so. Both documents were distributed with the aim 
of facilitating IRB approval at individual HgbSCCs. 
Resources Needed:
The goal of this project was to identify clinical case patients 
while minimizing the burden of data collection to center staff. 
Labor shortage was a common hurdle to overcome at centers 
when working on case identification and data extraction. To 
assist with these concerns, RuSH project staff worked with 
providers at each center to ensure an effective IRB submission. 
In addition, RuSH project staff helped draft patient consent 
forms, develop data entry tools needed for data collection, 
and offered their own services to perform site visits to centers 
to assist with review of patient records. As such, the resources 
required to complete clinical data collection included a 
substantial time commitment from and collaboration among 
team members, travel expenses associated with site visits 
to centers, and software to design and build a user-friendly 
database with an intuitive form of interface for data entry of 
patient information.
Lessons Learned: 
Outreach to providers and corresponding clinical data 
collection required a substantial time commitment, constant 
communication, and organization. Regular communication 
with providers and center staff throughout the IRB submission 
process and the subsequent data collection efforts were 
essential to ensure timely progress. It was essential to have all 
key documents (project protocol, letters, approvals, etc.) on file 
and accessible to external partners working with RuSH team 
members, as these documents provided the backbone of IRB 
submissions at individual centers. IRB approval of the RuSH 
project varied considerably among institutions. Therefore, it 
was also essential to be flexible and available when working 
with providers to assist them in preparing the materials needed 
for their IRB submissions, to assist in drafting documents as 
requested, and to provide answers to questions posed by IRB 
panelists. 
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It sometimes took months for an individual center to move 
through the steps from the initial decision to participate in 
RuSH, to an effective IRB submission, to performing case 
identification of patients. This preceded the actual data 
collection itself, which might have involved a site visit for record 
review and data extraction. It was important to allot enough 
time for this process. For future projects involving clinical data, 
it is recommended that—in addition to structuring the research 
design in compliance with privacy and HIPAA laws–a legislative 
mandate or letters from the proper authority granting access 
to clinical data be obtained. Also, additional labor and funding 
would be useful for the work involved in chart review and data 
extraction.
Outcome: 
A summary of our outreach efforts follows: 31 pediatric centers 
were contacted initially regarding RuSH clinical data collection; 
7 centers received IRB approval and have begun the case 
identification and data collection process; 9 other centers have 
shown interest in participation, but are at various stages in the 
IRB discussion and approval process; seven centers opted out 
of participation due to resource issues, such as time and labor; 
and no response was received from 8 centers after repeated 
attempts at contact. At each of the approved centers, the 
New York RuSH team was able to identify cases not previously 
identified through NBS. The clinical data, representing several 
hundred cases, should shed some light on the prevalence 
of hemoglobinopathies and the most common treatments 
administered to patients. The current list of IRB approved 
centers comprises: New York-Presbyterian/Weill Cornell Medical 
Center, New York Methodist Hospital, Brookdale University 
Hospital and Medical Center, Staten Island University Hospital, 
Interfaith Medical Center, Women & Children’s Hospital of 
Buffalo, and Bronx-Lebanon Hospital Center. 
Sustainability/Translation: 
Now that the groundwork has been laid and contacts have 
been established with providers in treatment centers around 
NYS, and particularly in the New York City area, continued 
communication and collaboration might continue past the 
end of the RuSH project period. The next step following this 
work will be to reach out to adult HgbSCCs. In previous RuSH 
community outreach projects, the NY RuSH team administered 
surveys to providers at adult HgbSCCs to assess the long-
term health care status of patients, determine what clinical 
information was collected by the centers, and explore the 
possibility of data collection and sharing of patient data with 
the RuSH project team. Based on the responses received, 
available clinical data from patients seen at these centers will be 
sought, following the same protocol established for outreach 
to pediatric centers. In future data collection efforts, funding 
would be an essential component to success, as staffing is 
necessary for the work involved in data review and data entry 
of hundreds of cases. Hospitals have limited resources to 
allocate to these tasks without funding for necessary staff.
Contact Information:
Ying Wang, PhD, MPH
wxy01@health.state.ny.us
518-402-7716
www.wadsworth.org/newborn/RuSH/rush_overview.html
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Notes:

National Center on Birth Defects and Developmental Disabilities
Division of Blood Disorders
For more information contact:
Centers for Disease Control and Prevention
National Center on Birth Defects and Developmental Disabilities
Division of Blood Disorders
1600 Clifton Road MS E-87
Atlanta, GA 30333
800-CDC-INFO (800-232-4636) 
TTY: (888) 232-6348
24 Hours/Every Day
cdcinfo@cdc.gov 
